Extended Data Fig. 6. Inhibition of RAS signal transduction pathways.
a, Western blots of isogenic RAS-less MEF cell lines harboring an exogenous, wild-type (WT) or mutant KRAS, or BRAFV600E transgene, treated with indicated concentrations of trametinib or DMSO control for 24 h. Data shown are representative of 3 independent experiments. b,c, Western blots of KRAS mutated cell lines treated with RMC-7977 at indicated concentrations for 4 h (b), or treated with RMC-7977 (100 nM) or DMSO control for indicated time points. c, Data shown are representative of 2 independent experiments.